Thidiazuron decreases epithelial-mesenchymal transition activity through the NF-kB and PI3K/AKT signalling pathways in breast cancer.
Biomarkers
Breast Neoplasms
/ metabolism
Caspase 3
/ metabolism
Cell Line, Tumor
Cell Movement
Cell Survival
/ drug effects
DNA Fragmentation
Epithelial-Mesenchymal Transition
/ drug effects
Female
Humans
Immunohistochemistry
Matrix Metalloproteinases
/ metabolism
NF-kappa B
/ metabolism
Phenylurea Compounds
/ pharmacology
Phosphatidylinositol 3-Kinases
/ metabolism
Poly(ADP-ribose) Polymerases
/ metabolism
Protein Binding
Proto-Oncogene Proteins c-akt
/ metabolism
Signal Transduction
/ drug effects
Thiadiazoles
/ pharmacology
Thidiazuron
breast cancer
epithelial-mesenchymal transition
matrix metalloproteinase
metastasis
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
01
07
2020
revised:
15
10
2020
accepted:
25
10
2020
pubmed:
8
11
2020
medline:
15
5
2021
entrez:
7
11
2020
Statut:
ppublish
Résumé
Breast cancer is the major type among the women population globally. The treatment of cancer metastasis has made modest progress due to multiple factors. Thidiazuron (TDZ) is a novel plant growth regulator that has been shown to have anticancer effects. Therefore, we explored the anti-metastatic potentials of TDZ in cell lines by assessing its potential to suppress the epithelial-mesenchymal transition (EMT). We pretreated the BEAS-2B and breast cancer (MDA-MB-231) cells with TDZ and deliberated alteration in a cell viability, mammosphere, migration, NF-кB signalling, PI3K/AKT signalling and matrix metalloproteinase (MMP) expression and analysed the EMT induction by TGF-β/TNF-α-stimulated BEAS-2B cells. Treatment with TDZ (5-50 μmol) diminished the migration and invasion of the extremely metastatic MDA-MB-231 cells. Additionally, TDZ treatment led to down-regulation of uPAR, uPA, VEGF and MMP-2/-9 expression and up-regulation of TIMP-1/2 expression in these cells. Furthermore, TDZ treatment blocked invasion and EMT in non-tumorigenic BEAS-2B epithelial cells stimulated with TGF-β/TNF-α.TDZ prevents EMT and may thus block metastasis of breast cancer cells.
Identifiants
pubmed: 33159487
doi: 10.1111/jcmm.16079
pmc: PMC7754050
doi:
Substances chimiques
Biomarkers
0
NF-kappa B
0
Phenylurea Compounds
0
Thiadiazoles
0
thidiazuron
0091WH7STF
Poly(ADP-ribose) Polymerases
EC 2.4.2.30
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Caspase 3
EC 3.4.22.-
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14525-14538Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Int J Oncol. 2016 Sep;49(3):1230-40
pubmed: 27573547
Breast Cancer Res. 2003;5(2):101-6
pubmed: 12631389
J Med Genet. 2004 Mar;41(3):161-70
pubmed: 14985374
Cancer Biol Ther. 2018;19(10):858-868
pubmed: 29580128
Clin Cancer Res. 2006 Sep 15;12(18):5369-76
pubmed: 17000670
Cell Adh Migr. 2015;9(4):317-24
pubmed: 26241004
Apoptosis. 2004 Nov;9(6):667-76
pubmed: 15505410
J Cell Mol Med. 2020 Dec;24(24):14525-14538
pubmed: 33159487
Clin Exp Metastasis. 2010 May;27(5):361-9
pubmed: 20461449
Am Soc Clin Oncol Educ Book. 2015;:e2-7
pubmed: 25993174
Int J Oncol. 2014 Aug;45(2):887-94
pubmed: 24867464
BMC Cancer. 2011 Feb 16;11:73
pubmed: 21324165
Cell Mol Biol Lett. 2019 Jan 10;24:6
pubmed: 30651744
J Breast Cancer. 2018 Mar;21(1):70-79
pubmed: 29628986
Pharmacol Res. 2019 Apr;142:1-13
pubmed: 30735802
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
PLoS One. 2013 Oct 04;8(10):e77281
pubmed: 24124614
Toxicol Appl Pharmacol. 2008 Jan 15;226(2):178-91
pubmed: 17961621
Genes Dev. 2013 Oct 15;27(20):2192-206
pubmed: 24142872
Sci Rep. 2019 Feb 19;9(1):2318
pubmed: 30783124
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
Cancer Cell. 2009 May 5;15(5):416-28
pubmed: 19411070
Cancer Lett. 2015 Apr 1;359(1):20-35
pubmed: 25597784
N Engl J Med. 1986 Dec 25;315(26):1650-9
pubmed: 3537791
J Cell Physiol. 2019 Feb 5;:
pubmed: 30723913
J Interferon Cytokine Res. 2019 Jan;39(1):39-55
pubmed: 30321090
J Exp Clin Cancer Res. 2019 May 8;38(1):186
pubmed: 31068208
Int J Med Sci. 2017 Sep 30;14(12):1284-1291
pubmed: 29104486
Res Vet Sci. 2014 Apr;96(2):288-91
pubmed: 24565002
Semin Cancer Biol. 2017 Jun;44:25-42
pubmed: 28323021
Mol Carcinog. 2015 Oct;54(10):971-85
pubmed: 24797723
Oncogene. 2011 Mar 24;30(12):1436-48
pubmed: 21057535
PLoS One. 2015 Nov 18;10(11):e0143285
pubmed: 26580399
BMC Cancer. 2019 Jan 18;19(1):88
pubmed: 30658600
J Agric Food Chem. 2012 Apr 25;60(16):4083-9
pubmed: 22480333
Phytomedicine. 2010 Jul;17(8-9):581-8
pubmed: 20096548
J Photochem Photobiol B. 2017 Aug;173:493-498
pubmed: 28668518
J Clin Oncol. 2000 Mar;18(5):1135-49
pubmed: 10694567
Cancer Lett. 2011 Dec 22;312(2):178-88
pubmed: 21924548
Cancer Lett. 2014 Jul 10;349(1):35-44
pubmed: 24704156
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
Int Arch Allergy Immunol. 2011;155(2):119-28
pubmed: 21196756
Curr Cancer Drug Targets. 2013 Nov;13(9):963-972
pubmed: 24168186
Differentiation. 2002 Dec;70(9-10):561-73
pubmed: 12492497
Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30
pubmed: 17512904
Oncogene. 2014 May 1;33(18):2307-16
pubmed: 23686305
Pharmacol Ther. 2018 Feb;182:80-94
pubmed: 28834698
Mol Cell Biochem. 2018 Jan;438(1-2):47-57
pubmed: 28744809
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
Genes Dev. 2003 May 15;17(10):1253-70
pubmed: 12756227
Food Chem Toxicol. 2019 Feb;124:219-230
pubmed: 30529123
Life Sci. 2019 Mar 1;220:186-193
pubmed: 30682342